Kevin A. Lobo's departure as Chief Executive Officer of Stryker Corp was reported, effective January 1, 2027; the filing names no successor. As of November 10, 2026, Stryker Corp has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 20, 2026 to November 9, 2026, naming 1 appointment and 1 departure (Form 8-K, October 6, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Stryker Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: James E. Davis · Role: Director · 8-K, 2026-11-09
- · In / out: Out · Person: Kevin A. Lobo · Role: Chief Executive Officer · Effective: 2027-01-01 · 8-K, 2026-10-06
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-05-20
Stryker Corp reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-20 to 2026-11-09. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Stryker Corp files it.
Also on the record for Stryker Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 6.73% of the class | 5%+ stakes | Source |
| April 14, 2026 | Stake report, Schedule 13D/A, by STRYKER RONDA E | 4% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G/A, by GREENLEAF TRUST | 4.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Stryker Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Stryker Corp and the records around it.
Stryker Corp elsewhere on the record
- 5%+ stake filings Apr 2026
- Who owns it
Companies that share a holder
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Stryker Corp
Get an email when Stryker Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Stryker Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Stryker Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Stryker Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-09 | In | Director | 8-K, 2026-11-09 | ||
| 2026-10-06 | Out | Chief Executive Officer | 2027-01-01 | 8-K, 2026-10-06 | |
| 2026-05-20 | Reported | not named in the filing | 8-K, 2026-05-20 |
Who leads Stryker Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Kevin A. Lobo, departure reported, effective 2027-01-01 (filed 2026-10-06). No successor is named in these filings.
- Director: James E. Davis, appointed (filed 2026-11-09).
New leaders reset buying decisions — get the Full Report on Stryker Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Stryker Corp, with the record behind each one.
Find candidates like Director at Stryker CorpEvery change, in the filing's words
Appointed: James E. Davis, Director
On November 3, 2026, the Board of Directors of Stryker Corporation (the "Company") increased the number of authorized directors from 11 to 12 and elected James E. Davis to fill the resulting vacancy.
- Mr. Davis's election will become effective on January 1, 2027, and he has not been appointed to any committee of the Board at this time.
- Mr. Davis has been CEO and President of Quest Diagnostics ("Quest") since November 2022 and assumed the role of Chairman of the Quest Board in April 2023.
- Mr. Davis joined Quest in 2013 as Senior Vice President, Diagnostic Services and was named Senior Vice President, Operations in February 2014.
- Before joining Quest, he served as CEO of InSightec, Inc., a global medical device company.
- Prior to that, Mr. Davis spent two decades in senior management roles across General Electric's healthcare and aviation businesses, including five years leading General Electric's MRI business.
- Before General Electric, Mr. Davis led the development of strategic and operating initiatives for clients of McKinsey & Company, Inc. Mr. Davis will be compensated for his services consistent with the Company's other non-employee directors, as described in the Company's proxy statement for its 2026 annual meeting of stockholders filed with the Securities and Exchange Commission (the "SEC") on March 23, 2026.
Departing: Kevin A. Lobo, Chief Executive Officer, effective 2027-01-01
Stryker Corporation (the "Company") announced on October 6, 2026 that Kevin A. Lobo will resign from his role as Chief Executive Officer ("CEO") of the Company on December 31, 2026 and transition to the role of Executive Chair of the Board of Directors of the Company (the "Board"), effective January 1, 2027 (the "CEO Transition") and that Spencer S. Stiles, who currently serves as President and Chief Operating Officer of the Company, has been appointed CEO of the Company, effective January 1, 2027.
- In connection with Mr. Stiles's appointment as CEO, the Board also increased the size of the Board from 10 to 11 and appointed Mr. Stiles to serve as a member of the Board, effective January 1, 2027.
- Mr. Stiles has not been appointed to any committee of the Board at this time.
- Prior to that, he served as Group President, Orthopaedics, from 2019.
- Throughout his 27-year career at the Company, he has held leadership roles across Orthopaedics as well as MedSurg and Neurotechnology and has overseen international regions and key supporting functions.
- Mr. Stiles graduated from Miami University with a bachelor's degree in business and received his MBA from the University of Nebraska.
- Transition Agreement with Mr. Lobo On October 5, 2026, the Company entered into a letter agreement with Mr. Lobo (the "Transition Agreement"), pursuant to which (1) he will continue to serve as CEO of the Company through December 31, 2026, and (2) as of January 1, 2027, he will begin serving as Executive Chair of the Board.
- Mr. Lobo's annual base salary, annual bonus target and employee benefit plan eligibility will remain unchanged following the CEO Transition, but he will not be eligible to receive any new stock awards while serving as Executive Chair of the Board.
Reported
Stryker Corporation (the "Company") announced on May 20, 2026 that William E. Berry, Jr. has decided to retire from his role as Vice President, Chief Accounting Officer of the Company effective September 1, 2026 and that Emily Baculik, who currently serves as Vice President, Corporate Controller, will also serve as chief accounting officer of the Company effective September 1, 2026.
- Prior to that, she was Vice President, Finance for the Spine Division from September 2022 to November 2024 and Senior Director, Finance from June 2021 to September 2022.
- Ms. Baculik has more than 20 years of finance and accounting experience with publicly traded companies and has prior experience in external financial reporting, technical accounting, compliance and controllership at Eaton, Rockwell Collins, Ingersoll Rand and U.S. Steel.
- Ms. Baculik graduated from the University of Notre Dame with a bachelor's degree in history and earned a master's degree in accounting from The Ohio State University.
- Transition Agreement with Mr. Berry Mr. Berry has entered into a Transition Agreement with the Company pursuant to which he will continue to be employed as Advisor to the Chief Financial Officer from September 1, 2026 until August 15, 2027 (the "Advisory Period").
- During the Advisory Period, Mr. Berry will continue to receive base salary at his current annual rate of $510,000, and he will continue to be eligible to receive a 2026 incentive bonus with a target bonus percentage of 50% of his annual salary subject to the terms of the applicable bonus plan.
- Mr. Berry will not be eligible for an annual incentive bonus or any prorated bonus for services provided during 2027.
Tools for this story
Each opens in a new tab, filled in for Stryker Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.